Source: Health Canada shortage reports · Updated Oct 26, 2026
Some Efavirenz products are in shortage in Canada (2 of 7 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Jul 13, 2027.
An antiviral (non-nucleoside reverse transcriptase inhibitor) used as part of combination therapy for HIV.
Products affected
2 / 7
In shortage since
May 14, 2025
Est. full return
Jul 13, 2027
Reports on file
14
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
MYLAN-EFAVIRENZ
600MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02381524 · since May 4, 2026, est. end Jul 13, 2027 · Disruption of the manufacture of the drug.
Active shortage
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762 · since May 14, 2025, no end estimate · Disruption of the manufacture of the drug.
Resolved
JAMP-EFAVIRENZ
600MG · TABLET · JAMP PHARMA CORPORATION
DIN 02458233 · ended Jul 31, 2025 · Disruption of the manufacture of the drug.
Discontinued
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762
Resolved
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762 · ended Apr 7, 2025 · Disruption of the manufacture of the drug.
Resolved
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762 · ended Jul 5, 2023 · Disruption of the manufacture of the drug.
Resolved
TEVA-EFAVIRENZ
600MG · TABLET · TEVA CANADA LIMITED
DIN 02389762 · ended Jul 5, 2023 · Disruption of the manufacture of the drug.
Discontinued
SUSTIVA 200MG
200MG · CAPSULE · BRISTOL-MYERS SQUIBB CANADA
DIN 02239888
Discontinued
SUSTIVA 50MG
50MG · CAPSULE · BRISTOL-MYERS SQUIBB CANADA
DIN 02239886
Discontinued
SUSTIVA TABLETS
600MG · TABLET · BRISTOL-MYERS SQUIBB CANADA
DIN 02246045
Resolved
JAMP-EFAVIRENZ
600MG · TABLET · JAMP PHARMA CORPORATION
DIN 02458233 · ended Jul 19, 2022 · Disruption of the manufacture of the drug.
Resolved
SUSTIVA 50MG
50MG · CAPSULE · BRISTOL-MYERS SQUIBB CANADA
DIN 02239886 · ended Dec 10, 2020 · Delay in shipping of the drug.
Showing 12 of 14 reports. All reports are on file with Health Canada.
What's happening
Efavirenz is currently affected by 2 active shortage reports filed with Health Canada by MYLAN PHARMACEUTICALS ULC, TEVA CANADA LIMITED.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Efavirenz is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AG).
Recent changes
Oct 26, 2026
New report filed
Common questions
What is Efavirenz used for?
An antiviral (non-nucleoside reverse transcriptase inhibitor) used as part of combination therapy for HIV.
When will Efavirenz be back in stock in Canada?
The latest manufacturer estimate is Jul 13, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Efavirenz in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.